ADXS-504

· Advaxis, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ADXS-504, covering 2025-04-25 to 2025-04-25. Get the full timeline:

Most recent: Clinical Trial Update: Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer [Phase 1]